



The Safety and Therapeutic Effectiveness of Universal Donor Frozen RBC, Frozen Platelets and Frozen Plasma Stored at -80°C in Mechanical Freezers to Treat Wounded Casualties

C.R. Valeri* and G. R. Giorgio

NBRL, Inc., USA

*Corresponding author: C.R. Valeri, NBRL, Inc., 195 Bournehurst Drive, Plymouth, MA 02360, USA, E-mail: navblood@yahoo.com

Abstract

For the past 15 years, the Netherlands military have utilized universal donor RBC, platelets and plasma all frozen and stored at -80°C in a mechanical freezer to treat wounded casualties with excellent clinical results and without adverse events. The data reported by the NBRL over the past 50 years and the Netherlands military over the past 15 years now recommend that the Food and Drug Administration, the American Red Cross, Health and Human Service, and the Department of Defense should support the use of universal donor frozen group O positive and O negative RBC, frozen group O leukoreduced platelets and frozen AB plasma. All the blood products frozen and stored at -80°C provide safe and therapeutic effective blood products to treat patients. The frozen blood products will eliminate or reduce the severe adverse events of mortality and morbidity associated with the current FDA approved red blood cell products, platelet products and plasma products. The universal donor group O positive and O negative frozen RBC, group O leukoreduced single donor frozen platelets, and AB frozen plasma obtained from male donors will provide blood products that are compatible with acceptable in vivo survival and function to treat patients and reduce or eliminate the severe adverse events associated with the current FDA approved blood products.

Introduction

For the past 50 years the Naval Blood Research Laboratory, Boston, MA has been supported by the U.S. Navy to study the safety and therapeutic effectiveness of frozen RBC, frozen platelets and frozen plasma to treat wounded casualties. Human RBC treated with 40% W/V glycerol with the removal of the supernatant glycerol prior to freezing at -80°C for 10 years, thawed, deglycerolized, using the Haemonetics Blood Processor ACP215 instrument and stored in AS-3 at 4°C for 2 weeks; single donor group O leukoreduced platelets treated with 6% DMSO, concentrated to remove the supernatant DMSO prior to freezing of the platelets in a -80°C mechanical freezer for at least 2 years, thawed, diluted with 0.9% NaCl and stored at room temperature for 6 hours and group AB plasma frozen at -80°C for at least 10 years, thawed and stored at 4°C for 24 hours are now available to treat wounded casualties. For the past 15 years frozen group O Rh positive and group O Rh negative RBC, frozen single donor leukoreduced group O platelets concentrated to remove the

supernatant DMSO prior to freezing at -80°C and after thawing resuspended in AB plasma, and frozen AB plasma have been used by the Netherlands military to treat wounded casualties. The Netherlands military no longer use non-tested fresh whole blood to treat military and civilian wounded personnel in the Middle East conflicts. The Netherlands military in combat zones in Afghanistan, Iraq, and Bosnia has reported significant improvement in the survival from 44% to 84% for wounded casualties who required more than 10 units of red blood cells in a 24 hour period transfused with frozen blood products at the ratio of 4 units of frozen group O red blood cells, 3 units of frozen AB plasma, and one unit of single donor group O leukoreduced 2.5 - 3.0 X 10¹¹ platelets treated with 5% DMSO, the supernatant DMSO removed prior to freezing at -80°C, thawed, diluted and resuspended in a unit of AB plasma and stored at room temperature for 6 hours with no adverse effects.

The -80°C mechanical freezer contains a dual-cascade air-cooled compressor and is attached to a carbon dioxide tank to be triggered to add the liquid carbon dioxide when the temperature decreases to -65°C because of electrical or mechanical failures can be deployed in combat areas by the military. Frozen blood products consisting of RBC, platelets, and plasma can be transported using dry ice in insulated containers which maintain the temperature of -65°C to -80°C as documented by the experience of the U.S. Navy during the Vietnam War in 1968 to 1974 and the Netherlands military in the Middle East combat zones in Iraq, Afghanistan, and Bosnia in 2000 to 2012.

The recent paper by Henkelman S and Rakhorst G in Transfusion [1] "Does modern combat still need fresh whole blood transfusions?" reported that the Dutch military blood bank eliminated the use of fresh whole blood on site and implemented the routine use of frozen group O Rh positive and group O Rh negative deglycerolized RBC, frozen single donor leukoreduced group O platelets, and frozen AB plasma to treat wounded casualties in war zones. The RBC, platelets, and plasma are frozen and stored at -80°C in mechanical freezers. Following thawing, the deglycerolized RBC are stored at 4°C in the additive solution AS-3 for 14 days, the thawed AB plasma stored at 4°C for 7 days, and the thawed single donor leukoreduced platelets containing 2.5 to 3.0 X 10¹¹ platelets in AB plasma stored at room temperature for 6 hours.

Universal donor group O Rh positive and group O Rh negative RBC, group O single donor leukoreduced platelets resuspended in AB plasma and AB plasma eliminate the need to provide fresh whole blood to treat patients subjected to traumatic injuries in war zones. The current method to freeze single donor leukoreduced platelets containing 2.5 to 3.0×10^{11} platelets equivalent to the number of platelets isolated from 4 to 6 units of fresh whole blood treated with 5% DMSO in 0.9% NaCl, the supernatant DMSO removed prior to freezing and storage in a -80°C mechanical freezer, and following thawing resuspended in a unit of AB plasma eliminate the need to provide the platelets in fresh whole blood and single donor leukoreduced apheresed platelets stored at room temperature for 5 days with agitation.

Freezing at 2-3 C per minute by storage of human platelets treated with 6% DMSO in a -80°C mechanical freezer produces a bimodal population of human and baboon platelets. One population of platelets that circulates and the other population of platelets that function to reduce non-surgical bleeding. In the baboon autologous platelets frozen with 6% DMSO, thawed, washed and resuspended in autologous plasma produced a population of GpIb normal and reduced factor V binding baboon platelets with an in vivo recovery of 48% and a linear lifespan of less than 6 days. The other population of GpIb reduced and increased factor V binding baboon platelets was rapidly removed from the circulation within 5 minutes and was associated with a reduction in nonsurgical blood loss [2].

Automation of RBC glycerolization using the high separation bowl attached to the Haemonetics ACP215 disposable glycerolizing set has simplified glycerolization of both non rejuvenated and rejuvenated RBC [3]. The procedure to deglycerolize RBC frozen with 40% W/V glycerol using the ACP215 reduces the glycerol concentration to < 1%, reduces the level of PIPA solution used to biochemically modify the RBC prior to freezing, reduces the WBC to a mean of 1×10^7 in the unit, and reduces the plasma to less than 5% [4].

Leukoreduced and washed deglycerolized RBC stored at 4 C in AS-3 for 2 weeks is the ideal RBC product to prevent transfusion-related acute lung injury (TRALI) and systemic inflammatory response syndrome (SIRS) [4].

NBRL has simplified the RBC freezing by removing the supernatant glycerol prior to freezing. NBRL has simplified freezing of platelets by removal of the supernatant DMSO prior to freezing. Removal of the supernatant DMSO removes about 95% of the DMSO and eliminates the need for post-thaw washing prior to transfusion [4]. Lelkens CCM and associates have reported the use by the Netherlands military of: Group O Rh positive and group O Rh negative RBC frozen with 40% W/V glycerol and stored at -80°C for at least 10 years; group O single donor leukoreduced platelets frozen with 5% DMSO with removal of the supernatant DMSO solution before freezing and storage at -80°C for at least 2 years and following thawing resuspended in AB plasma; and AB plasma stored at -30°C and then at -80°C for at least 10 years to treat patients who required these blood products [5-7].

Lelkens CCM and associates experience in the Netherlands military have demonstrated for the first time that frozen RBC, frozen platelets and frozen plasma stored at -80°C can be used to treat patients without the need for a "walking blood bank" and fresh whole blood [5,8,9]. Henkelman S and G Rakhorst in Transfusion [1] have reported the safety and therapeutic effectiveness of frozen RBC, frozen platelets, and frozen plasma stored in -80°C mechanical freezers to treat combat casualties without the need for fresh whole blood [10].

The Survival and Function of Preserved Red Cells and Platelets

One should not assume that because the survival of preserved RBC and preserved platelets is satisfactory, their ability to function following transfusion will also be satisfactory. Yet, while the FDA requires that preserved RBC have 24-hour post transfusion survival

of 75%, they make no regulations requiring that the RBC function satisfactorily immediately or shortly after transfusion. The FDA also assumes that when a sick patient received 25% of nonviable compatible RBC with a transfusion, the recipient will suffer no adverse effects. Although there are no data to show how many nonviable compatible RBC can be safely administered to sick patients, it is known that if a patient receives 10 units of RBC with a 24-hour post transfusion survival value of 75%, then 2.5 units of the RBC will be nonviable. The removal of these compatible nonviable RBC by the reticuloendothelial (RE) system may interfere with the removal of infectious disease agents, tumor cells, and particulate matter present in the stored RBC, and affect cellular and humoral immunity.

The FDA considers preserved platelets to be acceptable if the in vivo recovery is 66% that of fresh platelets and the lifespan is 50% that of fresh platelets but again offers no guidelines with regard to hemostatic function. Although in vitro levels of RBC ATP, DPG and p50 levels give an indication of the in vivo function of the preserved RBC, there are no in vitro tests that can predict the in vivo function of fresh and preserved platelets. Studies at the NBRL have shown that when preserved platelets function satisfactorily they will correct an aspirin induced prolonged bleeding time in normal volunteers and in healthy baboons [11].

The survival and function of preserved red blood cells are critical especially for patients with cerebral, myocardial or renal insufficiency and for patients with a nonsurgical bleeding diathesis. Studies at the NBRL have shown that preserved red blood cells stored in CPDA-1 or in any one of the additive solutions CPD/AS-1, CP2D/AS-3 or CPD/AS-5 for only 2 weeks have acceptable 24-hour post transfusion survival values of greater than 75% and only moderately impaired oxygen transport function at the time of infusion [12].

Liquid preserved autologous platelets that were stored at room temperature ($22 \pm 2^\circ\text{C}$) with agitation for 48 hours were found to have acceptable in vivo recovery and survival and were able to function to reduce an aspirin-induced prolonged bleeding time in normal volunteers and healthy baboons. On the other hand, when autologous baboon platelets were stored at room temperature for 3 or 5 days, they did circulate but did not reduce the prolonged bleeding time in aspirin treated healthy baboons [11,13-15].

Between 1988 and 1992, the NBRL collaborated with Shukri Khuri, Chief of Surgery and Chief of Cardiothoracic Surgery at the West Roxbury Veteran's Administration Hospital, to evaluate liquid preserved and washed previously frozen platelets transfused to cardiopulmonary bypass (CPB) patients. The previously frozen platelets had been frozen with 6% DMSO at 2-3°C per minute and stored at -80°C for a mean of 289 ± 193 days (SD) and for as long as 2 years and were washed prior to transfusion. A prospective randomized study was conducted in 73 patients undergoing CPB surgery. The study was designed to measure nonsurgical blood loss, i.e. blood loss not related to the surgical procedure and not controlled by surgical intervention after neutralization of the heparin with protamine sulfate. Nonsurgical blood loss was collected intraoperatively and during the 24-hour postoperative period.

The allogeneic single donor washed previously frozen platelets transfused to these patients had been processed in the following manner. The platelets were frozen at the University of Massachusetts in Worcester, Massachusetts, and transported in the frozen state with dry ice to the NBRL where they were stored in -80°C mechanical freezers for at least 3 months. They were then transported in the frozen state in insulated containers with dry ice to West Roxbury Veteran's Administration Hospital blood bank where they were stored at -80°C in mechanical freezers. After thawing, the platelets were washed and stored in ACD plasma at room temperature without agitation for as long as 5 hours. The platelets were transfused to the patients after the CPB surgery.

The prospective randomized study compared the need for allogeneic RBCs and fresh frozen plasma (FFP) to treat the nonsurgical blood loss in two groups of patients. One group received previously

frozen washed platelets and the other group received liquid preserved platelets. The patients who received previously frozen washed platelets showed a reduction in the nonsurgical blood loss and required fewer units of allogeneic RBCs and FFP than the patients who received the liquid preserved platelets stored with agitation at 22°C for a mean of 3.4 days. The platelet survival 2 hours after transfusion was 37% for patients who received the liquid preserved platelets compared to 24% for the patients who received the previously frozen washed platelets [14].

The total number of liquid preserved platelets infused was $6.9 \times 10^{11} \pm 3.9 \times 10^{11}$ per patient which was significantly greater than the $4.5 \times 10^{11} \pm 2.1 \times 10^{11}$ per patient for the previously frozen washed platelets. The difference was the result of the freeze-thaw-wash (FTW) recovery value of 70% for the previously frozen washed platelets. The *in vivo* recovery and function of the liquid preserved and cryopreserved platelets in these patients were similar to values seen in studies in which liquid preserved and cryopreserved platelets were transfused to aspirin-treated human volunteers and baboons. Although in the patients in this study, the *in vivo* recovery values were higher for the liquid preserved allogeneic platelets than for the washed previously frozen platelets, nonsurgical blood loss was lower in the patients who received the washed previously frozen platelets and they required fewer units of allogeneic RBCs and FFP [14].

In the paper in *Transfusion* [16] Bilgin YM and associates reported the postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. The authors reported that to improve hemostasis, platelets and fresh frozen plasma (FFP) are often transfused in the perioperative and postoperative period, however, neither the efficacy nor the safety of platelets and plasma transfusions have been demonstrated. The authors failed to report that a paper written by Khuri SF and associates was published in *J Thorac Cardiovasc Surg* 117: 172-184, 1999 compared the effects of cryopreserved and liquid preserved platelets on hemostasis and blood loss after cardiopulmonary bypass [14]. The cryopreserved platelets produced a significantly greater reduction in nonsurgical blood loss and the reduced need for liquid preserved red blood cells and fresh frozen plasma. Khuri SF and associates studied the *in vivo* recovery and function of cryopreserved platelets compared to liquid preserved platelets in a prospective randomized study in 73 patients undergoing cardiopulmonary bypass surgery. The liquid preserved platelets were stored with agitation at 22°C for as long as 5 days and single donor platelets were frozen with 6% DMSO at 2 to 3°C per minute by storage in a -80°C mechanical freezer for as long as 2 years, thawed, and washed prior to transfusion. The study was designed to measure nonsurgical blood loss in the patients after neutralization of the heparin with protamine sulphate. Nonsurgical blood loss was collected intraoperatively and during the 24-hour postoperative period. The prospective randomized study compared the need for liquid preserved red blood cells stored at 4°C and fresh frozen plasma stored at -20°C to treat the nonsurgical blood loss in the two groups of patients. One group received previously frozen single donor washed platelets and the other group receive liquid preserved single donor or pooled platelets stored at 22°C for a mean of 3.4 days with agitation. Although the *in vivo* recovery values of the liquid preserved platelets were higher than those of the previously frozen washed platelets, the patients who received the washed previously frozen platelets had significantly reduced nonsurgical blood loss and required fewer units of liquid preserved red blood cells and fresh frozen plasma than the patients who received liquid preserved platelets stored at room temperature for a mean of 3.4 days with agitation. No adverse effects were observed in either group [14,16].

In 2000 the NBRL modified the method of freezing platelets with 6% DMSO at 2-3°C per minute by storage in a -80°C mechanical freezer. With the modified method the supernatant DMSO was removed before the platelets were frozen and the previously frozen platelets were not washed prior to transfusion [17]. When platelets are washed the *in vitro* recovery is reduced by 25%. With the modified method, the thawed platelets are not washed but are diluted

with 10 ml to 20 ml of 0.9% NaCl and stored without agitation at room temperature for 6 hours. The freeze-thaw (FT) recovery is approximately 90%, with 5-8% platelets microparticles, *in vivo* recovery is 25-30%, and the linear lifespan is 7 days. The diluted platelets have a bimodal population: one population is GPIb-normal and annexin V-reduced and the other is GPIb-reduced with increased annexin V binding.

Mechanical freezers maintained at -80°C are needed for the storage of these safe and therapeutically effective frozen blood products for use by both the military and civilian communities to supplement the liquid preservation of RBC stored at 4°C, platelets stored at 22°C with agitation, and fresh frozen plasma and cryoprecipitate stored at -20°C.

Studies at the NBRL have shown that previously frozen washed RBC have not been associated with the severe adverse events observed with the current FDA-approved blood products. Frozen RBC stored at -80°C has been successfully deployed during the Vietnam War and the Persian Gulf War by the U.S. Navy and the Department of Defense [4].

The past 50 years have seen many significant improvements in cryopreservation procedures. Removing supernatant glycerol from RBC and DMSO from platelets prior to freezing has simplified the postthaw processing. Platelets diluted with 10 ml to 20 ml of 0.9% NaCl after thawing can be stored at room temperature without agitation for 6 hours prior to use. With the functionally closed Haemonetics ACP215 instrument, deglycerolized RBC can be stored at 4°C in AS-3 (Nutricel) for 2 weeks. With this instrument, the volume of solution needed to deglycerolize RBC is now only 1.6 liters compared to 3.2 liters with the Haemonetics Blood Processor 115 and 6.8 liters with the Huggins cytoglomerator [4].

The Netherlands military has been actively freezing universal donor group O Rh positive and group O Rh negative RBC, single donor leukoreduced frozen group O platelets and frozen AB plasma in -80°C mechanical freezers. These frozen blood products have been collected from donors meeting FDA regulations that were safely transported and stored in -80°C mechanical freezers without breakage. These blood products have been obtained from screened blood donors and tested for the mandated infectious markers prior to freezing and have eliminated the need for fresh whole blood or apheresed leukoreduced platelets stored at room temperature for 5 days with agitation to treat patients suffering traumatic injuries with therapeutically effective outcomes and without adverse events.

The utilization of the -80°C mechanical freezers to freeze RBC, platelets, and plasma by the Netherlands military has demonstrated the safety and therapeutic effectiveness of these frozen blood products without the need for fresh whole blood or apheresed platelets to treat military and civilian casualties requiring more than 10 units of red blood cells within a 24-hour period in combat zones in Afghanistan and Iraq. It is of interest that the Netherlands investigators pioneered the use of liquid nitrogen to freeze blood products but now utilize -80°C mechanical freezers to freeze red blood cells, platelets and plasma to treat combat casualties.

Dr. John Badloe at the ATACCC meeting on August 16, 2010 at St. Pete, Florida reported that in Afghanistan from 2000 to 2010, 859 patients received 6,335 blood products which include 1918 units of frozen red blood cells, 841 units of liquid preserved red blood cells, 2560 units of frozen plasma and 1,016 units of frozen platelets with no transfusion reactions. Fresh whole blood was not used by the Netherlands military because the fresh whole blood could not be tested prior to transfusion for the mandated infectious disease markers whereas all the frozen blood products were tested for the mandated infectious disease markers prior to freezing from the donors who were screened prior to donation.

Dr. John Badloe reported the Netherlands military experience in the Middle East war zones using frozen blood products, i.e. frozen group O Rh positive and group O Rh negative RBC, frozen AB

plasma, and frozen group O single donor leukoreduced $2.5 - 3.0 \times 10^{11}$ platelets with removal of supernatant DMSO, all frozen and stored at -80°C in mechanical freezers at ratio of 1:2:1 increased survival of patients from 44% to 84%. No adverse events were reported and only frozen blood products without the need for fresh whole blood were safe, available, effective and efficient in the treatment of patients requiring at least 10 units of red blood cells in a 24-hour period for resuscitation.

The abstract which was reported by Dr. John Badloe and Dr. Femke Noorman from the Ministry of Defense, Military Blood Bank, Leiden, Netherland at the Annual meeting of the AABB, San Diego, CA October 22-25, 2011 confirm the procedures provided by the NBRL, Boston, MA to freeze human RBC, plasma, and platelets in -80°C mechanical freezers. This report by the Netherlands military demonstrates that fresh whole blood advocated by Colonel William Crosby and the U.S. Army is no longer used by the Netherlands military and the fresh whole blood can be replaced by frozen RBC, frozen plasma, and frozen platelets significantly improved survival of the massively transfused patients [9].

A comparison between the U.S. Army procedures and the Netherlands procedures to provide blood products to treat combat casualties needs to be performed regarding the logistic requirements, outdatedness of blood products, compatibility, cost of transportation, availability, safety and therapeutic effectiveness. The quality and quantity of the blood products to resuscitate casualties requiring at least 10 units of red blood cells in a 24-hour period and the mortality and morbidity utilizing the U.S. Army procedures to the Netherlands procedures in combat zones need to be compared. The Netherlands military has documented that -80°C frozen red blood cells, plasma and platelets were deployable, available, compatible, safe and effective in the treatment of trauma patients with or without massive blood loss in military theatre.

Dr. Femke Noorman and Dr. John Badloe and associates presented one oral presentation and three (3) poster presentations at the AABB annual meeting from October 6-9, 2012 in Boston, MA [10]. Studies can now be done to compare the safety and therapeutic effectiveness of universal donor RBC frozen for at least 10 years, group O platelets frozen for at least 2 years, and AB plasma frozen for at least 10 years (all blood products frozen and stored at -80°C with a range of -65°C to -90°C) without the need for fresh whole blood to the current use of fresh whole blood, liquid preserved RBC stored at 4°C in additive solutions for as long as 42 days, single donor leukoreduced apheresed platelets stored with agitation at room temperature for 5 days, and fresh frozen plasma and cryoprecipitate stored at -20°C for one year on mortality and morbidity in the recipients.

In the study to compare the procedures utilized by the Netherlands military to the current FDA approved procedures to provide blood products; the volume and composition of the resuscitation fluids used with the blood products need to be reported. The morbidity and mortality associated with the current FDA approved blood products can be compared to the use of frozen RBC, frozen platelets, and frozen plasma without the need for fresh whole blood and apheresed platelets which Netherlands military has successfully utilized to treat combat casualties in war zones from August 2006 to February 2012; 2,175 units of frozen RBC, 1,070 units of frozen platelets, 3,001 units of frozen plasma and 879 units of liquid preserved RBC stored at 4°C were transfused to 1,011 casualties without any transfusion reactions observed. The blood products were obtained from pre-screened donors and the blood products were tested for infectious diseases prior to freezing [10].

In the response to the paper "Transfusion of older stored blood and risk of death" published by Wang D and associates in Transfusion [18] an editorial was written by Warkentin TE and Eikelboom JW "Old blood bad? Either the biggest issue in transfusion medicine or a nonevent" in Transfusion [19]. These authors stated "the demonstration of an association (if indeed there is one) between the age of transfused blood and outcome would be useless if one could

not do anything about it". This editorial failed to acknowledge that freeze preservation of red blood cells, platelets and plasma has been reported to provide safe and therapeutically effective blood products from 2006 to 2012 to successfully treat 1,011 civilian and military casualties in war zones in Iraq and Afghanistan by the Netherlands military using -80°C mechanical freezers to freeze and store universal donor group O Rh positive and group O Rh negative red blood cells, single donor leukoreduced group O platelets, and group AB plasma without the need for fresh whole blood and apheresed platelets.

It is imperative that civilian and military blood banking communities change their methods of collection and preservation of blood products if they are really interested in providing patients with the safest and most therapeutically effective blood products and in avoiding risks associated with transfusion.

The primary concern of the blood banking community appears to be the extension of the length of storage of the blood products. This practice may make inventory management easier, but it certainly will not improve patient outcomes or provide patients with the safest and most therapeutically effective blood products. Of course, cost must be a consideration but, in the long run, the recipient's health should be paramount. With regard to the mortality and morbidity associated with the severe adverse reactions to transfused blood products, it is important to note that Medicare has informed hospitals that they will no longer pay for long stays in hospitals when proper care could have prevented the increased hospitalization. A concerted effort must be made to determine why the transfused blood products are causing mortality and morbidity associated with post transfusion infection, TRALI and SIRS, and what can be done to eliminate the causes. The health of the patient must be of greater importance than making blood collection and inventory management easier.

There have been several retrospective studies reporting severe adverse events of mortality and morbidity associated with post transfusion infection, TRALI, and SIRS in patients undergoing cardiac surgery, after massive transfusions for severe traumatic injuries, and after transfusions for elective and emergency indications. After 35 days of storage at 4°C in additive solutions, RBC have 24-hour post transfusion survival values of 75% but do not function satisfactorily. For RBC to function satisfactorily shortly after transfusion, they should be stored at 4°C for no more than 2 weeks. Yet while the FDA requires a 24-hour post transfusion survival value of 75%, they make no requirement for the function of the transfused RBC. It has been shown that red blood cells that circulate and function immediately or shortly after transfusion exert a very important hemostatic effect to reduce the bleeding time and nonsurgical blood loss in anemic and thrombocytopenic patients. Greater restoration of hemostasis is seen with viable and functional RBC transfusions than with platelets or plasma even through the platelets and plasma may have satisfactory viability and function.

The Food and Drug Administration (FDA), Health and Human Services (HHS), the American Red Cross (ARC) and the blood banking community have focused on further testing of blood products to reduce the rate of disease transmission. Another consideration is the disinfection of red blood cells, platelets, and plasma. What is more important, they should be looking at the quality of the blood products being transfused. We know that the length of storage of blood products affects their survival and function and that transfusion of nonviable compatible RBC, antibodies to granulocytes and WBC HLA antigens, and biologically active substances affect the patient's clinical outcome. One of the easiest ways to prevent the severe adverse effects that have been observed is to ensure that the transfused blood products survive and function at an optimum level and that the levels of antibodies to granulocytes and WBC HLA antigens and biologically active substances are reduced. The best way to ensure this is to store liquid preserved human red blood cells at 4°C in additive solutions for no more than 2 weeks and leukoreduced platelets at room temperature for no more than 2 days. These liquid preserved blood products can be used in conjunction with frozen RBC, frozen platelets and frozen plasma all stored in a -80°C mechanical freezer.

The reluctance of the blood banking community to consider any changes that could improve the safety and therapeutic effectiveness of blood products brings to mind two very relevant quotations: one by Maurice Maeterlinck is that “At every crossway on the road that leads to the future, every progressive spirit is opposed by a thousand men appointed to guard the past”. The other by Winston Churchill is that “Occasionally man will stumble on the truth but will manage to pick himself up and continue on as if nothing had happened.” It is time now to investigate the current blood banking procedures and to seek ways to improve them.

The Netherlands military have successfully deployed -80°C mechanical freezers to store frozen universal donor group O Rh positive and group O Rh negative RBC treated with 40% W/V glycerol with the removal of the supernatant glycerol prior to freezing for at least 10 years at -80°C in mechanical freezers, thawed, washed using the Haemonetics Blood Processor ACP215 instrument and stored at 4°C in AS-3 for 2 weeks that circulate and function immediately or shortly after transfusion: single donor leukoreduced group O platelets treated with 5% DMSO, the supernatant DMSO removed, the DMSO treated platelets frozen and stored at -80°C for at least 2 years, thawed, diluted with a unit of AB plasma and stored at room temperature without agitation for 6 hours that circulate and function shortly after transfusion; and group AB plasma, frozen at -80°C for at least 10 years thawed and stored at 4°C for 7 days that produce a hemostatic effect.

References

1. Henkelman S, Rakhorst G (2012) Does modern combat still need fresh whole blood transfusions? *Transfusion* 52: 2272-2273.
2. Barnard MR, MacGregor H, Ragno G, Pivacek LE, Khuri SF, et al. (1999) Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity. *Transfusion* 39: 880-888.
3. Valeri CR, Ragno G, Van Houten P, Rose L, Rose M, et al. (2005) Automation of the glycerolization of red blood cells with the high-separation bowl in the Haemonetics ACP 215 instrument. *Transfusion* 45: 1621-1627.
4. Valeri CR, Ragno G (2006) Cryopreservation of human blood products. *Transfus Apher Sci* 34: 271-287.
5. Lelkens CC, Koning JG, de Kort B, Floot IB, Noorman F (2006) Experiences with frozen blood products in the Netherlands military. *Transfus Apher Sci* 34: 289-298.
6. Noorman F, Badloe JF (2012) -80°C frozen platelets - efficient logistics, available, compatible, safe and effective in the treatment of trauma patients with or without massive blood loss in military theatre. *Transfusion* 52: S53-030H.
7. Noorman F, Strelitsid R, Badloe JF (2012) -80°C frozen platelets are activated compared to 24 hour liquid stored platelets and quality of frozen platelets is unaffected by a quick preparation method (15 min) which can be used to prepare platelets for the early treatment of trauma patients in military theatre. *Transfusion* 52: SP23.
8. Noorman F et al. (2009) Frozen -80°C red cells, plasma and platelets in combat casualty care. *Transfusion* 49: 28A.
9. Badloe J, Noorman F (2011) The Netherlands experience with frozen -80°C red cells, plasma and platelets in combat casualty care S1-301. *Transfusion* 51.
10. Noorman F, Badloe JF (2012) -80°C frozen red blood cells, plasma and platelets: efficient logistics, available, compatible, safe and effective in the treatment of trauma patients with or without massive blood loss in military theatre. *Transfusion* 52: SP383.
11. Valeri CR, Khuri S, Ragno G (2007) Nonsurgical bleeding diathesis in anemic thrombocytopenic patients: role of temperature, red blood cells, platelets, and plasma-clotting proteins. *Transfusion* 47: 206S-248S.
12. Valeri CR, Ragno G (2010) An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products. *Transfus Apher Sci* 42: 223-233.
13. Handin RI, Valeri CR (1971) Hemostatic effectiveness of platelets stored at 22 degrees C. *N Engl J Med* 285: 538-543.
14. Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, et al. (1999) Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 117: 172-184.
15. Valeri CR, MacGregor H, Giorgio A, Ragno G (2002) Circulation and hemostatic function of autologous fresh, liquid preserved, and cryopreserved baboon platelets transfused to correct an aspirin-induced thrombocytopeny. *Transfusion* 42:1206-1216.
16. Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Vamvakas EC, et al. (2011) Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. *Transfusion* 51: 2603-2610.
17. Valeri CR, Ragno G, Khuri S (2005) Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at -80 degrees C without postthaw processing. *Transfusion* 45: 1890-1898.
18. Wang D, Sun J, Solomon SB, Kleing G, Natanson C (2012) Transfusion of older stored blood and risk of death: a meta-analysis. *Transfusion* 52: 1184-1195.
19. Warkentin TE, Eikelboom JW (2012) Old blood bad? Either the biggest issue in transfusion medicine or a nonevent. *Transfusion* 52: 1165-1167.